Impact of prior authorizations, Dr. Price confirmation, dermatology robots, atopic dermatitis links, psoriasis and bone fractures. View this email in your browser
Dermatology World Weekly
February 1, 2017
The October issue of Dermatology World is now available online at This month’s issue discusses how dermatologists improve access via referrals. Also, don’t miss DW’s in-depth look at practical strategies for dealing with high deductibles. Cannabinoids in dermatology? Learn more in this month’s iteration of the DW Trending video series. Check out the tablet-friendly version or visit
The burden of prior authorizations: How bad is it really?

The U.S. Food and Drug Administration (FDA) has cleared the StarWalker® MaQX Q-Switched laser system to be used for treating tattoos, pigmented and vascular lesions, acne and scars, and hair reduction. Fotona, the manufacturer of the device, has indicated that the laser system will be available for purchase in the United States immediately. 

Tattoos have become increasingly popular over the years, yet dermatologists often see patients looking to remove the body art as well. Read more about the latest technology in tattoo removal in Dermatology World.

Related Links:

Experimental psoriasis drug offers better clearance

Results from a recent study published in the New England Journal of Medicine, suggest that Johnson & Johnson’s guselkumab — an anti-IL-23 therapy — may be more effective in treating psoriasis than TNF-alpha inhibitors.

Related Links:

Links to this month's issue

Sunscreen comparison
Improving access



Copyright © 2017 American Academy of Dermatology Association, All rights reserved.

Unsubscribe from Dermatology World Weekly   

Our address is:

Contact Us | Manage your email preferences | Opt out of all of all emails